10.17.18
Johnson & Johnson
3Q Revenues: $20.3 billion (+4%)
3Q Earnings: $3.9 billion (+5%)
YTD Revenues: $61.2 billion (+9%)
YTD Earnings: $12.3 billion (+2%)
Comments: Pharmaceutical sales were $10.3 billion in the quarter, up 7%. Domestic sales increased 5%, and international sales increased 10%, which reflected an operational increase of 13% and a negative currency impact of 4%. Remicade sales were down 16% to $1.4 billion, due to competition. Simponi sales were up 13% to $536 million. Stelara sales were $1.3 billion, up 17%. Xarelto sales were $612 million in the quarter, down 4%. Zytiga sales were $958 million, up 43%. Imbruvica sales were $705 million, up 38%. Darzalex sales were $498 million, up 57%. Invega Sustenna sales were $749 million, up 17%. Worldwide Consumer sales were $3.4 billion in the quarter, up 2%. Medical Device sales were $6.6 billion in the quarter, down .2%.
3Q Revenues: $20.3 billion (+4%)
3Q Earnings: $3.9 billion (+5%)
YTD Revenues: $61.2 billion (+9%)
YTD Earnings: $12.3 billion (+2%)
Comments: Pharmaceutical sales were $10.3 billion in the quarter, up 7%. Domestic sales increased 5%, and international sales increased 10%, which reflected an operational increase of 13% and a negative currency impact of 4%. Remicade sales were down 16% to $1.4 billion, due to competition. Simponi sales were up 13% to $536 million. Stelara sales were $1.3 billion, up 17%. Xarelto sales were $612 million in the quarter, down 4%. Zytiga sales were $958 million, up 43%. Imbruvica sales were $705 million, up 38%. Darzalex sales were $498 million, up 57%. Invega Sustenna sales were $749 million, up 17%. Worldwide Consumer sales were $3.4 billion in the quarter, up 2%. Medical Device sales were $6.6 billion in the quarter, down .2%.
